Anixa Biosciences Company Insiders
| ANIX Stock | USD 3.16 0.01 0.32% |
Anixa Biosciences' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Anixa Biosciences suggests that vertually all insiders are extremely bullish. Anixa Biosciences employs about 5 people. The company is managed by 4 executives with a total tenure of roughly 8 years, averaging almost 2.0 years of service per executive, having 1.25 employees per reported executive.
| Amit Kumar Chairman Chairman of the Board and Presidentident, CEO |
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
| 2025-01-28 | Arnold M Baskies | Acquired 5000 @ 2.82 | View | ||
| 2025-01-23 | Lewis H Titterton Jr | Acquired 2000 @ 2.91 | View | ||
| 2025-01-21 | Lewis H Titterton Jr | Acquired 6000 @ 2.59 | View | ||
| 2025-01-17 | Lewis H Titterton Jr | Acquired 10000 @ 2.57 | View | ||
| 2025-01-15 | Michael Catelani | Acquired 9289 @ 2.15 | View | ||
| 2024-07-30 | Lewis H Titterton Jr | Acquired 21646 @ 3.06 | View | ||
| 2024-07-26 | Arnold M Baskies | Acquired 5000 @ 3.09 | View | ||
| 2024-06-13 | Lewis H Titterton Jr | Acquired 405 @ 2.7 | View | ||
| 2024-06-10 | Lewis H Titterton Jr | Acquired 330 @ 2.6 | View | ||
| 2024-06-07 | Amit Kumar | Acquired 25000 @ 2.41 | View | ||
| 2024-04-09 | Lewis H Titterton Jr | Acquired 15009 @ 3.28 | View |
Monitoring Anixa Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Anixa |
Anixa Biosciences' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Anixa Biosciences' future performance. Based on our forecasts, it is anticipated that Anixa will maintain a workforce of slightly above 20 employees by April 2025.Anixa Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.3842) % which means that it has lost $0.3842 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6261) %, meaning that it created substantial loss on money invested by shareholders. Anixa Biosciences' management efficiency ratios could be used to measure how well Anixa Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.7 in 2025. Return On Capital Employed is likely to drop to -0.87 in 2025. At this time, Anixa Biosciences' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 1.2 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 250.2 K in 2025.Common Stock Shares Outstanding is likely to rise to about 38.5 M in 2025, whereas Net Loss is likely to drop (12.8 M) in 2025.
Anixa Biosciences Workforce Comparison
Anixa Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 1,062. Anixa Biosciences adds roughly 5.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Anixa Biosciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Anixa Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Anixa Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Anixa Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-12-01 | 1.0 | 1 | 1 | 16,000 | 16,000 |
| 2023-12-01 | 2.0 | 2 | 1 | 17,117 | 16,000 |
| 2023-09-01 | 0.6 | 3 | 5 | 165,500 | 287,217 |
| 2022-09-01 | 0.5 | 2 | 4 | 680,000 | 1,471,900 |
| 2022-06-01 | 8.0 | 8 | 1 | 265,095 | 16,000 |
| 2021-06-01 | 11.0 | 11 | 1 | 2,916,634 | 1,500,000 |
| 2021-03-01 | 5.0 | 5 | 1 | 85,600 | 200,000 |
| 2019-12-01 | 8.0 | 8 | 1 | 845,912 | 0.00 |
| 2019-09-01 | 3.8 | 19 | 5 | 1,419,000 | 440,000 |
| 2018-09-01 | 2.3333 | 7 | 3 | 321,842 | 20,000 |
| 2018-06-01 | 4.0 | 4 | 1 | 4,100,000 | 25,000 |
| 2017-12-01 | 1.0 | 1 | 1 | 2,400 | 2,400 |
| 2017-09-01 | 1.7222 | 31 | 18 | 2,118,400 | 606,000 |
| 2017-06-01 | 7.0 | 7 | 1 | 35,995 | 5,995 |
| 2016-12-01 | 0.4 | 2 | 5 | 52,000 | 30,804 |
| 2016-06-01 | 3.75 | 15 | 4 | 14,004 | 4,000 |
| 2015-12-01 | 0.1667 | 1 | 6 | 4,000 | 20,000 |
| 2015-03-01 | 1.4815 | 40 | 27 | 28,591,583 | 27,230,000 |
| 2014-12-01 | 1.0 | 1 | 1 | 70,000 | 70,000 |
| 2014-09-01 | 3.5 | 7 | 2 | 3,500,000 | 2,000 |
| 2014-06-01 | 2.0 | 2 | 1 | 305,000 | 5,000 |
| 2013-12-01 | 5.0 | 5 | 1 | 6,050,000 | 16,000 |
| 2013-09-01 | 0.4 | 6 | 15 | 2,397,235 | 2,592,450 |
| 2012-12-01 | 2.0 | 4 | 2 | 1,180,000 | 8,000,000 |
| 2012-09-01 | 6.5 | 26 | 4 | 2,886,000 | 12,000,000 |
| 2011-06-01 | 2.0 | 4 | 2 | 1,260,000 | 560,000 |
| 2011-03-01 | 8.0 | 8 | 1 | 6,720,000 | 700,000 |
| 2009-12-01 | 2.5 | 5 | 2 | 1,360,000 | 200,000 |
| 2007-12-01 | 4.0 | 4 | 1 | 1,435,000 | 0.00 |
| 2007-09-01 | 1.0 | 3 | 3 | 1,220,000 | 1,220,000 |
| 2006-12-01 | 0.375 | 6 | 16 | 1,900,000 | 2,365,905 |
| 2006-09-01 | 1.0 | 1 | 1 | 20,000 | 20,000 |
| 2006-03-01 | 1.0 | 1 | 1 | 10,550 | 15,000 |
| 2005-12-01 | 4.0 | 4 | 1 | 1,200,000 | 15,000 |
| 2005-09-01 | 1.0 | 1 | 1 | 16,025 | 10,000 |
| 2004-06-01 | 5.5 | 11 | 2 | 860,000 | 40,000 |
Anixa Biosciences Notable Stakeholders
An Anixa Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Anixa Biosciences often face trade-offs trying to please all of them. Anixa Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Anixa Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Amit Kumar | Chairman of the Board and Presidentident, CEO | Profile | |
| John Roop | Senior Engineering | Profile | |
| Pamela Garzone | Chief Officer | Profile | |
| Thomas Schlumpberger | Ex Diagnostics | Profile |
About Anixa Biosciences Management Performance
The success or failure of an entity such as Anixa Biosciences often depends on how effective the management is. Anixa Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Anixa management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Anixa management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.67) | (0.70) | |
| Return On Capital Employed | (0.83) | (0.87) | |
| Return On Assets | (0.67) | (0.70) | |
| Return On Equity | (0.72) | (0.76) |
Please note, the imprecision that can be found in Anixa Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Anixa Biosciences. Check Anixa Biosciences' Beneish M Score to see the likelihood of Anixa Biosciences' management manipulating its earnings.
Anixa Biosciences Workforce Analysis
Traditionally, organizations such as Anixa Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Anixa Biosciences within its industry.Anixa Biosciences Manpower Efficiency
Return on Anixa Biosciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.5M | |
| Net Loss Per Executive | 3.2M | |
| Working Capital Per Employee | 3.8M | |
| Working Capital Per Executive | 4.7M |
Additional Tools for Anixa Stock Analysis
When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.